Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report.

Autor:	de Weger VA; Department of Medical Oncology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Schutte T; Department of Medical Oncology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Konings IRHM; Department of Medical Oncology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands., Menke-van der Houven van Oordt CW; Department of Medical Oncology, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands. c.menke@amsterdamumc.nl.
Jazyk:	angličtina
Zdroj:	Journal of breast cancer [J Breast Cancer] 2023 Oct; Vol. 26 (5), pp. 519-523.
DOI:	10.4048/jbc.2023.26.e38
Abstrakt:	Trastuzumab deruxtecan (T-DXd) is used to treat human epidermal growth factor receptor 2-positive advanced breast cancer. Interstitial lung disease (ILD) is a severe adverse event associated with T-DXd. Current guidelines recommend permanent discontinuation of T-DXd after Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 2 ILD. Here, we describe a case of successful rechallenge with T-DXd after CTCAE grade 2 treatment-induced ILD. After discontinuation of T-DXd, ILD was treated with steroids until complete resolution. Given the initial beneficial antitumor response, retreatment was discussed during disease progression. In a shared decision with the patient, T-DXd was restarted at the lowest registered dose, along with low-dose steroids. ILD did not reoccur. Importantly, both clinical and radiological responses to the treatment were observed, with an improvement in the patient's quality of life. This case demonstrates that retreatment with T-DXd after a grade 2 ILD event is feasible and yields clinical benefit. Competing Interests: Inge R.H.M. Konings reports travel expenses from AstraZeneca/Daiichi Sankyo and research funding from Novartis and Gilead for research related to breast cancer outside of the submitted work. Catharina Willemien Menke-van der Houven van Oordt reports travel expenses from AstraZeneca/Daiichi Sankyo and research funding from Astra Zeneca, Pfizer, and G1 Therapeutics for research related to breast cancer outside the submitted work. Other authors declare that they have no competing interests. (© 2023 Korean Breast Cancer Society.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu